results for pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer
Published 6 years ago • 150 plays • Length 2:50Download video MP4
Download video MP3
Similar videos
-
0:29
adjuvant treatment for high risk hr breast cancer | esmo 2023 breast cancer highlights
-
1:42
the case for neoadjuvant pembrolizumab in tnbc
-
38:22
adjuvant/neoadjuvant therapy for breast cancer: updates and molecular predictors of benefit
-
1:07
phase ii results for pembrolizumab monotherapy in metastatic tnbc
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
2:05
adding nivolumab to neoadjuvant chemo improves response rate for high risk er her2− breast cancer
-
0:55
neoadjuvant treatment approach for her2 positive breast cancer
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
6:45
her2 /er- breast cancer: neoadjuvant therapy options
-
3:28
neoadjuvant treatment strategies for her2-positive breast cancer
-
22:50
neoadjuvant therapy for her2-positive breast cancer - dr. scott christensen
-
1:07:43
new & supporting data for optimizing therapy in her2 breast cancer | dr. mahtani & dr. schwartzberg
-
1:00
utilizing neoadjuvant immunotherapies in patients with er , her2- primary breast cancer
-
1:03
remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
-
1:01
dr. hamilton discusses challenges with approved treatments for her2-positive breast cancer
-
3:52
neoadjuvant approaches for early-stage her2 breast cancers
-
3:51
adjuvant t-dm1 therapy for early-stage her2 breast cancer
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer